Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. It is developing COYA 101, an autologous regulatory T-cell product candidate that has completed Phase 2a clinical trial for use in the treatment of Amyotrophic Lateral Sclerosis. The company's product candidates in IND-enabling studies include COYA 301, a low-dose interleukin 2 Treg-enhancing biologic, which is in Phase 2 clinical trial for use in the treatment of Frontotemporal Dementia; and COYA 302, a biologic combination for subcutaneous administration intended to enhance Treg function while depleting T effector function and activated macrophages for use in the treatment of neurodegenerative and autoimmune diseases. It is also developing COYA 201, an antigen directed Treg-derived exosome product candidate that is in preclinical stage for use in the treatment of neurodegenerative, autoimmune, and metabolic diseases; and COYA 206, an antigen directed Treg-derived exosome product candidate, which is in discovery stage. The company has a collaboration with Dr. Reddy's Laboratories SA for the development and commercialization of COYA 302, an investigational combination therapy for treatment of amyotrophic lateral sclerosis. The company was incorporated in 2020 and is headquartered in Houston, Texas. more
Time Frame | COYA | Sector | S&P500 |
---|---|---|---|
1-Week Return | -8.43% | 0.31% | -1.26% |
1-Month Return | -0.18% | 0.6% | -4.16% |
3-Month Return | -27.93% | -9.44% | -0.46% |
6-Month Return | -26.62% | -5.15% | 3.58% |
1-Year Return | 1.07% | 0.33% | 22.47% |
3-Year Return | 23.63% | 4.53% | 25.13% |
Dec '20 | Dec '21 | Dec '22 | Dec '23 | |||
---|---|---|---|---|---|---|
Total Revenue | - | - | - | 6.00M | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":100,"profit":true}] | |
Cost of Revenue | - | 16.13K | 27.36K | 27.36K | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":58.96,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] | |
Gross Profit | - | (16.13K) | (27.36K) | 5.97M | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":-0.27,"profit":false},{"date":"2022-12-31","value":-0.46,"profit":false},{"date":"2023-12-31","value":100,"profit":true}] | |
Gross Margin | - | (Infinity%) | (Infinity%) | 99.54% | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":null,"profit":false},{"date":"2022-12-31","value":null,"profit":false},{"date":"2023-12-31","value":100,"profit":true}] | |
Operating Expenses | 694.77K | 4.87M | 9.81M | 13.91M | [{"date":"2020-12-31","value":5,"profit":true},{"date":"2021-12-31","value":35.02,"profit":true},{"date":"2022-12-31","value":70.56,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] | |
Operating Income | (694.77K) | (4.87M) | (9.81M) | (7.90M) | [{"date":"2020-12-31","value":-69477000,"profit":false},{"date":"2021-12-31","value":-487031000,"profit":false},{"date":"2022-12-31","value":-981193900,"profit":false},{"date":"2023-12-31","value":-790334900,"profit":false}] | |
Total Non-Operating Income/Expense | - | (21.48K) | - | - | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":-2148200,"profit":false},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] | |
Pre-Tax Income | (733.20K) | (4.89M) | (12.24M) | (7.26M) | [{"date":"2020-12-31","value":-73319500,"profit":false},{"date":"2021-12-31","value":-489179200,"profit":false},{"date":"2022-12-31","value":-1224477600,"profit":false},{"date":"2023-12-31","value":-726398400,"profit":false}] | |
Income Taxes | (704.65) | (21.48K) | 2.43M | 723.85K | [{"date":"2020-12-31","value":-0.03,"profit":false},{"date":"2021-12-31","value":-0.88,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":29.75,"profit":true}] | |
Income After Taxes | - | (4.87M) | - | - | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":-487031000,"profit":false},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] | |
Income From Continuous Operations | - | (4.89M) | (12.24M) | (12.36M) | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":-489179200,"profit":false},{"date":"2022-12-31","value":-1224477600,"profit":false},{"date":"2023-12-31","value":-1236147900,"profit":false}] | |
Income From Discontinued Operations | - | - | - | - | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] | |
Net Income | (733.20K) | (4.87M) | (14.68M) | (7.99M) | [{"date":"2020-12-31","value":-73319500,"profit":false},{"date":"2021-12-31","value":-487031000,"profit":false},{"date":"2022-12-31","value":-1467761300,"profit":false},{"date":"2023-12-31","value":-798783600,"profit":false}] | |
EPS (Diluted) | - | - | (0.51) | (0.79) | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":-51.24,"profit":false},{"date":"2023-12-31","value":-79,"profit":false}] | |
These ratios help you determine the liquidity of the company. Higher is better.
COYA | |
---|---|
Cash Ratio | 13.39 |
Current Ratio | 15.31 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
COYA | |
---|---|
ROA (LTM) | -29.34% |
ROE (LTM) | -50.83% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
COYA | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.10 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.90 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
COYA | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 9.88 |
P/B | 2.95 |
Price/FCF | NM |
EV/R | 11.54 |
EV/Ebitda | NM |
Coya Therapeutics, Inc. Common Stock (COYA) share price today is $5.65
Yes, Indians can buy shares of Coya Therapeutics, Inc. Common Stock (COYA) on Vested. To buy Coya Therapeutics, Inc. Common Stock from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in COYA stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Coya Therapeutics, Inc. Common Stock (COYA) via the Vested app. You can start investing in Coya Therapeutics, Inc. Common Stock (COYA) with a minimum investment of $1.
You can invest in shares of Coya Therapeutics, Inc. Common Stock (COYA) via Vested in three simple steps:
The 52-week high price of Coya Therapeutics, Inc. Common Stock (COYA) is $10.69. The 52-week low price of Coya Therapeutics, Inc. Common Stock (COYA) is $4.75.
The price-to-earnings (P/E) ratio of Coya Therapeutics, Inc. Common Stock (COYA) is
The price-to-book (P/B) ratio of Coya Therapeutics, Inc. Common Stock (COYA) is 2.95
The dividend yield of Coya Therapeutics, Inc. Common Stock (COYA) is 0.00%
The market capitalization of Coya Therapeutics, Inc. Common Stock (COYA) is $94.40M
The stock symbol (or ticker) of Coya Therapeutics, Inc. Common Stock is COYA